medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Relative Pandemic Severity in Canada and Four Peer Nations During the SARS-CoV-2 Pandemic

Amy Peng[1], Alison E. Simmons[1], Afia Amoako[1], Ashleigh R. Tuite[1,2] and David N. Fisman[1]

From the Dalla Lana School of Public Health, University of Toronto[1], Toronto, Ontario, Canada and the Public Health Agency of Canada, Ottawa, Ontario, Canada

Address reprint requests and correspondence to:

David Fisman, MD MPH FRCP(C)

Room 686, 155 College Street, Toronto, Ontario, M5T 3M7

Email: david.fisman@utoronto.ca

The research was supported by a grant to DNF from the Canadians Institutes for Health Research (2019 COVID-19 rapid researching funding OV4-170360).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

Introduction: National responses to the SARS-CoV-2 pandemic have been highly variable, which may explain some of the heterogeneity in the pandemic's health and economic impacts across the world. We sought to explore the effectiveness of the Canadian pandemic response relative to responses in four peer countries with similar political, economic and health systems, and with close historical and cultural ties to Canada (the United States, United Kingdom, France, and Australia) from March 2020 to May 2022.

Methods: We used reported age-specific mortality data to generate estimates of pandemic mortality standardized to the Canadian population. Age-specific case fatality, hospitalization, and intensive care admission probabilities for the Canadian province of Ontario were applied to estimated deaths in order to calculate hospitalizations and intensive care admissions averted by the Canadian response. The monetary value of averted hospitalizations was estimated using cost estimates from the Canadian Institute for Health Information. Age-specific quality-adjusted life-years (QALY) lost due to fatality were estimated using published estimates. QALY were monetized using a net expected benefit approach.

Results: Relative to the United States, United Kingdom, and France, the Canadian pandemic response was estimated to have averted 94,492, 64,306 and 13,641 deaths respectively, with more than 480,000 hospitalizations averted, and 1 million QALY saved, relative to the United States. A United States pandemic response applied to Canada would have resulted in more than $40 billion in economic losses due to healthcare expenditures and lost QALY; losses relative to the United Kingdom and France would have been $21 billion and $5 billion respectively. By contrast, an Australian pandemic response would have averted over 28,000 additional deaths and averted nearly $9 billion in costs in Canada.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Conclusions: Canada outperformed peer countries that aimed for mitigation, rather than elimination, of SARS-CoV-2 in the first two years of the pandemic, likely because of a more stringent public health response to disease transmission. This resulted in substantial numbers of lives saved and economic costs averted. However, comparison with Australia demonstrates that an elimination focus would have allowed Canada to save tens of thousands of lives, and would have saved substantial economic costs.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

The global SARS-CoV-2 pandemic has taken a fearsome toll on mortality, life expectancy and population health globally, but not all countries have been impacted equally. The reasons for this heterogeneity are only partly understood; population age structure is a key contributor to SARS-CoV-2 severity (1, 2), but countries with older age distributions (such as Japan) have been less severely affected than high-income peers (3). Japan's early focus on the airborne nature of SARS-CoV-2, and the widespread acceptance of masking, may also have been important mitigators (3, 4). Marked heterogeneity in severity is seen across countries that have similar age structures, and which were slow to recognize airborne transmission of SARS-CoV-2.

A case in point is the differential severity of the pandemic in Canada and the United States; both are wealthy, federal democracies with advanced medical care systems. In both countries, the COVID-19 pandemic has had a major impact on population health and the economy. The similarities and differences between the two countries' healthcare systems have made cross-national comparisons an important source of insight into the strengths and weaknesses of their respective health systems (5). During the COVID-19 pandemic, both COVID-19 cases and deaths per capita have been substantially higher in the United States than in Canada (6). By contrast, Australia represents another reasonable comparator for Canada, with similarities in income, culture and governance, but which employed more stringent pandemic control measures, and which has had much lower per capita SARS-CoV-2 pandemic mortality as of May 2022 (7). The United Kingdom and France share ties of economy, culture and history with Canada (as hubs of the British Commonwealth, and La Francophonie, both of which include Canada), and may also represent appropriate comparators.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Debate in the Canadian public sphere around pandemic policy often focusses on whether Canada's approach to disease control should be more stringent or less stringent. Assuming that differences in outcomes were at least in part driven by policy, rather than the independent actions and choices of individuals, we sought to explore the differences in outcomes that Canada would have experienced over the first two years of the SARS-CoV-2 pandemic, had it followed the path of the United States, the United Kingdom, Australia, or France. We had previously performed such an analysis in March 2021, with comparison restricted to Canada and the United States (6). While our objective was not to perform a formal cost-utility analysis of the Canadian pandemic response relative to responses in these peer nations, the question of costs averted, or excess costs accrued, both through hospitalizations and premature loss of life, is an important one, and we incorporated simple valuations of these quantities into our analysis. These may help inform future cost-utility analyses on this question.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Methods

We obtained national COVID-19-attributed death estimates from Public Health Agency of Canada, and national health authorities for the United Kingdom, France, the United States and Australia to late April or early May of 2022, as available (7-11). Population estimates were obtained from national census agencies for all countries (12-16). We calculated the number of excess or deficit deaths that would have been expected in Canada under approaches employed in comparator countries using direct standardization (17). Because country death data were reported using slightly different age groupings, we reallocated Canadian deaths to mirror the distribution of SARS-CoV-2 deaths, by two-year age increments, in the province of Ontario (available to January 18, 2022). Standardized mortality ratios for Canada, relative to other countries, were estimated by dividing observed by expected deaths (i.e., the deaths that *would* have occurred with a US-, UK-, France- or Australia-equivalent response). 95% confidence limits for ln(SMR) were calculated by estimating standard errors as $(1/A+1/B)^{1/2}$, where A and B are death counts in each of the two comparator countries, as described in (17).

Observed deaths were subtracted from expected deaths to calculate deaths averted. We divided averted deaths by age-specific case-fatality estimates from Ontario to estimate averted cases. We applied age-specific risks of hospital admission and intensive care admission, derived from Ontario case data, to calculate hospital and intensive care admissions averted. We placed a monetary value on hospitalizations and ICU admissions averted based on Canadian cost estimates generated by the Canadian Institute for Health Information (18). The approach of Briggs et al., modified for the Canadian context by Kirwin et al., was used to estimate quality-adjusted life-years (QALY) lost for deaths occurring in each age group (19, 20). We monetized QALY losses averted by applying a net expected benefit approach, with QALY valued at

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

$30,000 as per Kirwin et al (20). We compared stringency of pandemic responses using the Oxford Government Coronavirus Response Tracker's Pandemic Stringency Index, obtained from (21). Stringency was plotted against time, and differences in stringency between Canada and other countries were evaluated with the Wiloxon rank-sum test. All input data are publicly available at https://figshare.com/articles/dataset/Estimated_Deaths_Intensive_Care_Admissions_and_Hospitalizations_Averted_in_Canada_during_the_COVID-19_Pandemic/14036549.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Results

Fewer SARS-CoV-2 related deaths per capita had occurred in Canada than in the United States in all age groups as of May 2022, with SMR significantly less than 1 for all age groups in Canada. A similar pattern was seen when Canada was compared to the United Kingdom, except in children aged 0-14, where there was no significant difference between the two countries (SMR 1.02, 95% CI 0.67 to 1.55). In comparison with France, Canada was found to have experienced significantly fewer deaths per capita in adults aged 40 to 89 years, more deaths than France in those aged 20-29 and 90 and over, and no difference in those under 20 years. When compared to Australia, Canada was found to have had significantly higher SARS-CoV-2 related per capita mortality in all age groups except those aged 10-19, where differences were not significant (SMR 2.24, 95% CI 0.81 to 6.16) (**Table 1**).

When compared to United States, France, and United Kingdom SARS-CoV-2 responses, Canada's response was estimated to have prevented 94,492 (93,593 to 95,360) deaths, 64,306 (63,394 to 65,189) and 13,641 (12,489 to 14,735) deaths, respectively. By contrast, an Australian response applied to Canada would have saved 28,400 (26,097 to 30,939) lives of the 40,278 that had been lost to SARS-CoV-2 as of May 2022 (**Table 2**). Distributions of deaths by age also differed markedly between the United States and the other countries analyzed. For example, half of deaths in the United States occurred in individuals under the age of 55; in other countries, half of fatalities occurred under the approximate age of 75, with the remainder occurring in those aged 75 and over (**Figure 1**). A similar divergence between the United States response and those in other countries was seen when we applied age-specific QALY losses to death data (**Figure 2**).

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

We estimated that Canada's response saved over 1 million QALYs, nearly 500,000 hospitalizations, and over 100,000 ICU admissions relative to what would have occurred with a response equivalent to that seen in the United States (**Table 2**). The value of QALY losses and hospitalizations averted is estimated to be approximately $43 billion, with $32 billion due to aversion of lost QALY, and the remainder due to averted hospitalizations. The Canadian response also saved QALY and averted hospitalizations and ICU admissions relative to United Kingdom and French responses, though in the case of France credible intervals for estimates of hospitalizations and ICU admissions averted, and costs saved, overlapped zero (cost savings, $4.88 billion, 95% CI -$1.61 to $7.42 billion). When compared to the Australian response, Canada's response was estimated to have resulted in approximately 230,000 additional QALY lost, over 80,000 excess hospital admissions, and over 15,000 excess ICU admissions as of May 2022, representing a loss of $8.78 ($6.36 to $32.57) billion (**Table 2**). Age-specific estimates of deaths, healthcare utilization and costs averted for each of the four comparator countries are available at https://figshare.com/articles/dataset/Estimated_Deaths_Intensive_Care_Admissions_and_Hospitalizations_Averted_in_Canada_during_the_COVID-19_Pandemic/14036549.

The stringency of the Canadian pandemic response from March 1, 2020 to May 1, 2022, was significantly higher than stringency in the United States, United Kingdom and France, but was also higher than Australian stringency ($P < 0.001$ for all comparisons) (**Supplementary Table and Figures**).

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Discussion

The cultural similarities and integrated economies of Canada and the United States, which also have very different health systems, has long encouraged comparative research between these two countries (5, 22-24). During the current SARS-CoV-2 pandemic, this type of research has continued, spurred in part by the remarkable difference in the pandemic's impact on Canada and the United States (25). Here, we demonstrate that application of age-specific US data to Canada results in a far deadlier pandemic, with a more than three-fold increase in total deaths relative to those that had occurred in Canada as of May 2022.

A challenge with this type of comparison is that the United States' pandemic response has emerged as a global outlier, with SARS-CoV-2 taking a far greater toll in terms of loss of life than in any other high income peer country. The outlier status of the United States has the effect of making Canada-U.S. comparisons predictable in result, perhaps unfairly elevating the effectiveness of the Canadian pandemic response. As such, we also evaluated Canada's response relative to the United Kingdom and France, the two European countries from whose colonies Canada was created, as well as Australia, which given cultural, political, economic, and historical similarities to Canada, is also a fair comparator.

We find that, as with the United States, application of the United Kingdom's pandemic response to Canada would have resulted in tens of thousands of additional deaths, as well as billions of dollars in excess economic losses. While Canada appears to have outperformed France as well, differences between these two countries are more modest. Australia emerges as a model of what Canada might have achieved by taking a more aggressive stance on disease control during the first two years of the SARS-CoV-2 pandemic; we estimate that over 75% of

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Canadian pandemic deaths to date could have been averted through an Australian response, with cost-savings of approximately $10 billion.

Our work complements that of Razak et al., who also found that Canada had outperformed most of its G10 peers (Japan excepted) with respect to pandemic attributable mortality (26). However, the use of standardization, as applied here, allows us to see that the Canadian approach was far more effective than the US and UK approaches in preventing deaths in younger adults, with consequently greater gains in quality-adjusted survival. As public health and government officials in these five countries likely had access to similar information for decision-making, differences in outcomes likely reflected active policy choices. The complexity of the pandemic, and societal responses to it, makes identification of causal factors challenging. Galvani et al. noted that a key difference between Canada and the United States may relate to universal public healthcare in the former (25); however, universal public healthcare is also available in Australia, France, and the United Kingdom. Razak et al. noted that Canada outperformed many high-income peer countries on vaccination (26). We have also suggested that cultural differences between countries, including differences in social capital and trust in government, may be important (27).

While Canada's pandemic response, as reflected in the Oxford Stringency Index, was more stringent on average than the responses in the United States, United Kingdom, and France, it was also more stringent than Australia's, suggesting that stringency alone cannot explain differences in outcomes. Data from Aknin et al. suggest that it may not have been stringency, but the decision to aim for elimination rather than mitigation, that resulted in the low stringency and low deaths seen in countries like Australia (28). Although more aggressive pandemic control strategies have been criticized over perceived negative mental health impacts, these authors also

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

demonstrated that the impact of excess pandemic deaths far outweighed the impact of public health interventions as a driver of negative mental health effects during the pandemic (28). That would suggest Canada's approach, in addition to saving more lives and costs than US and UK responses, may have been more protective of population mental health. More stringent control strategies have also been criticized as resulting in greater negative economic impacts, and indeed Canada's GDP declined by 1.6% in the first two years of the pandemic (26); however, the $43 billion Canada effectively gained by avoiding a US-style pandemic response represents over 2% of Canadian GDP (valued at around $2.1 trillion ($CDN)).

Our analysis has three key limitations; as noted above we have not attempted to capture mental health consequences of the pandemic, or their costs. Other important costs and impacts that we do not include, and which would likely further widen the gap in health and economic consequences between these peer countries, include disutility and lost earnings associated with hospitalization, long-term costs of chronic disease, including cardiac, respiratory and neurological disease, in those who survive SARS-CoV-2 infection, and the health, economic and societal impacts of parental loss due to the pandemic (29-32). A second limitation of our analysis is our use of Ontario-specific case fatalities, and hospitalization and intensive care admission risks, to estimate outcomes averted at a national level. We use these data for pragmatic reasons: they were the most complete, and granular, Canadian death data to which we had access. However, Ontario's epidemiology is likely similar to that of Canada overall, both because of similarities in demographics and health systems across the country, and also because the population of Ontario represents approximately 40% of the Canadian population, and 35% of Canada's COVID-19 case load, such that the Province's epidemiology strongly influences that of Canada as a whole. Lastly, we assume that attribution of COVID-19 deaths in Canada and

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

comparator countries occurred in a comparable manner. The best available data (based on ratios of reported COVID-19 mortality to all-cause excess mortality during the pandemic) suggest that this is likely to have been the case for Canada, the United States, and France; reporting of COVID-19 mortality may have been more accurate in the United Kingdom than in Canada, which would tend to exaggerate the differences in outcomes between these two countries. More accurate reporting of COVID-19 deaths in Australia would lead us to underestimate the degree to which this country outperformed comparator countries (33).

In summary, we find that Canada's relatively strong pandemic response during the first two years of the SARS-CoV-2 pandemic resulted in large numbers of deaths, hospitalizations and intensive care unit admissions averted relative to responses in the United States and United Kingdom, with more modest gains relative to France. A disease control stance focussed on elimination rather than mitigation, as was pursued in Australia during the same time period, would have resulted in further health and economic benefits.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 1 Cumulative Proportion of COVID-19 Attributable Death by Age, March 2020 to May 2022.

Ages represent the midpoints of age categories. For the oldest age categories in Canada (80 and over) and the United States (85 and over) we assigned an age of 90 years.



medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 2. Cumulative Proportion of COVID-19 Attributable Quality-adjusted Life Years (QALY) Loss by Age, March 2020 to May 2022.

Ages represent the midpoints of age categories. For the oldest age categories in Canada (80 and over) and the United States (85 and over) we assigned an age of 90 years.



Table 1. Standardized Mortality Ratios for the First Two Years of the SARS-CoV-2 Pandemic in Peer Countries as Compared to Canada

Age Group	Deaths	Population	Cumulative Mortality per 1000	Expected Deaths, Canadian Population	Observed Canadian Deaths	Standardized Mortality Ratio	95% CI
				United States			
0 to 17	1,045	73,284,400	0.01	103	37	0.35	0.25 - 0.49
18 to 29	6,257	52,870,600	0.12	700	136	0.19	0.16 - 0.23
30 to 39	18,148	43,375,000	0.42	2244	315	0.14	0.13 - 0.16
40 to 49	42,961	39,929,000	1.08	52,66	660	0.13	0.12 - 0.14
50 to 64	187,272	62,110,000	3.02	23,330	3,772	0.16	0.16 - 0.17
65 to 74	229,682	31,487,000	7.29	29,816	6,422	0.22	0.21 - 0.22
75 to 84	257,553	15,407,000	16.72	35,487	10,899	0.31	0.30 - 0.31
85 and over	255,780	5,893,000	43.40	37,824	18,038	0.48	0.47 - 0.48

Total	998,698	198,201,000		134,770	40,278		
				United Kingdom			
0 to 14	64	11,974,857	0.005	32	33	1.02	0.67 - 1.55
15 to 44	2,748	25,311,086	0.109	1,631	685	0.42	0.39 - 0.46
45 to 64	21,139	17,286,653	1.223	12,378	4,466	0.36	0.35 - 0.37
65 to 74	30,745	6,719,287	4.576	18,703	6,491	0.35	0.34 - 0.36
75 to 84	59,945	4,129,982	14.515	30,812	21,317	0.69	0.68 - 0.70
85 and over	78,125	1,659,369	47.081	41,028	7,286	0.18	0.17 - 0.18
Total	190,018	67,081,234		104,584	40,278		
				France			
0 to 9	37	7,706,041	0.005	19	29	1.54	0.95 - 2.50
10 to 19	31	8,421,914	0.004	15	15	0.98	0.53 - 1.82
20 to 29	147	7,525,983	0.020	99	128	1.29	1.02 - 1.63
30 to 39	465	8,279,577	0.056	301	315	1.05	0.91 - 1.21
40 to 49	1,337	8,572,713	0.156	763	660	0.87	0.79 - 0.95
50 to 59	4,576	8,813,899	0.519	2,664	1,862	0.70	0.66 - 0.74

60 to 69	13,344	8,000,803	1.668	8,074	4,349	0.54	0.52 - 0.56
70 to 79	26,358	5,959,261	4.423	13,862	8,633	0.62	0.61 - 0.64
80 to 89	43,387	3,214,055	13.499	18,460	13,844	0.75	0.74 - 0.76
90 and over	25,895	927,995	27.904	9,662	10,443	1.08	1.06 - 1.11
Total	115,577	67,422,241		53,919	40,278		
				Australia			
0 to 9	8	3,156,780	0.003	10	29	2.914	1.33 - 6.38
10 to 19	5	3,097,360	0.002	7	15	2.240	0.81 - 6.16
20 to 29	22	3,476,779	0.006	32	128	3.972	2.53 - 6.24
30 to 39	65	3,780,122	0.017	92	315	3.415	2.62 - 4.46
40 to 49	124	3,294,734	0.038	184	660	3.583	2.96 - 4.34
50 to 59	322	3,143,647	0.10	526	1,862	3.543	3.15 - 3.99
60 to 69	726	2,737,883	0.27	1,284	4,349	3.388	3.13 - 3.67
70 to 79	1,579	1,952,572	0.81	2,534	8,633	3.406	3.23 - 3.59
80 to 89	2,695	876,320	3.08	4,205	13,844	3.292	3.16 - 3.43
90 and over	1,925	221,945	8.67	3,003	10,443	3.477	3.31 - 3.65

Total	7,471	25,738,142	11,878	40,278

NOTE: CI , confidence intervals.

Table 2. Health Outcomes and Costs Averted in Peer Countries as Compared to Canada

Outcome	Comparator Country											
	United States	95% CI		United Kingdom	95% CI		France	95% CI		Australia	95% CI	
Deaths Averted	94,492	93,593 -	95,360	64,306	63,394 -	65,189	13,641	12,489 -	14,735	-28,400	-30,939 -	-26,097
Hospitalizations Averted	483,009	465,046 -	516,497	196,611	184,256 -	209,756	39,367	-251,172 -	81,790	-83,281	-1025190 -	11,763
ICU Admissions Averted	108,157	99,635 -	117,714	40,131	37,002 -	43,514	8,984	-80,090 -	1,728	-15,335	-152,386 -	-4,379
QALY Gained	1,060,180	943,164 -	1,172,874	569,981	514,483 -	635,306	133,517	133,490 -	186,367	-231,100	-310,449 -	-220,234
Hospitalization Costs Averted	10.73	10.32 -	11.47	4.37	4.09 -	4.66	0.87	-5.61 -	1.83	-1.85	-23.26 -	0.25
ICU Costs Averted	5.18	4.78 -	5.65	1.92	1.77 -	2.08	0.43	-3.97 -	0.04	-0.73	-6.89 -	-0.19
Hospitalization Costs Averted (non-ICU)	5.55	5.55 -	5.81	2.45	2.31 -	2.58	0.44	-1.64 -	1.78	-1.12	-16.37 -	0.44

Net Benefit of QALY Gained	31.81	28.29 - 35.19	17.10	15.43 - 19.06	4.01	4.00 - 5.59	-6.93	-9.31 - -6.61
Total Costs Averted	42.54	38.62 - 46.65	21.47	19.52 - 23.71	4.88	-1.61 - 7.42	-8.78	-32.57 - -6.36

NOTE: All costs are in billions of $CDN. QALY, quality-adjusted life year; CI, credible intervals derived via simulation.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

References

1. Levin AT, Meyerowitz-Katz G, Owusu-Boaitey N, Cochran KB, Walsh SP**.** Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. medRxiv 2020.07.23.20160895; doi: https://doi.org/10.1101/2020.07.23.20160895. 2020.
2. Fisman DN, Greer AL, Tuite AR**.** Age Is Just a Number: A Critically Important Number for COVID-19 Case Fatality. Ann Intern Med. 2020;173(9):762-3.
3. Oshitani H**.** COVID lessons from Japan: the right messaging empowers citizens. Nature. 2022;605(7911):589.
4. Craft L**.** Japan has long accepted COVID's airborne spread, and scientists say ventilation is key. Available via the Internet at https://www.cbsnews.com/news/coronavirus-japan-has-long-accepted-covids-airborne-spread-and-scientists-say-ventilation-is-key/. Last accessed July 8, 2022. CBS News; 2020.
5. Rouleau JL, Moye LA, Pfeffer MA, Arnold JM, Bernstein V, Cuddy TE, et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. N Engl J Med. 1993;328(11):779-84.
6. Fisman DN, Tuite AR**.** Estimated Deaths, Intensive Care Admissions and Hospitalizations Averted in Canada during the COVID-19 Pandemic. medRxiv. 2021:2021.03.23.21253873.
7. Australian Government Department of Health**.** Coronavirus (COVID-19) case numbers and statistics. Available via the Internet at https://www.health.gov.au/health-alerts/covid-

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

19/case-numbers-and-statistics#cases-and-deaths-by-age-and-sex. Last accessed June 7, 2022. 2022.

8. U.S. Centers for Disease Control and Prevention. Weekly Updates by Select Demographic and Geographic Characteristics. Available via the Internet at https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm. Last accessed June 7, 2022. 2022.

9. Public Health Agency of Canada. COVID-19 daily epidemiology update. Available via the Internet at https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html?stat=num&measure=deaths&map=pt#a2. Last accessed June 7, 2022. 2022. 2022.

10. Sante Publique France. L'épidémie de COVID-19 en France. Available via the Internet at https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19. Last accessed June 14, 2022. 2022.

11. U.K. Office of National Statistics. Deaths registered weekly in England and Wales, provisional. Available via the Internet at https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/weeklyprovisionalfiguresondeathsregisteredinenglandandwales. Last accessed June 14, 2022. 2022.

12. Statistics Canada. Population estimates on July 1st, by age and sex. Table: 17-10-0005-01 (formerly CANSIM 051-0001). Available via the Internet at https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000501. Last accessed June 14, 2022. 2021.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

13. United States Census Bureau. Age and Sex Tables. Available via the Internet at https://www.census.gov/topics/population/age-and-sex/data/tables.html. Last accessed June 14, 2022. 2021.

14. United Kingdom Office for National Statistics. Population estimates. Available from the Internet at https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates. Last accessed June 14, 2022. 2022.

15. Institut national de la statistique et des etudes economiques. Demographic balance sheet 2019. Available via the Internet at https://www.insee.fr/en/statistiques/2382597?sommaire=2382613. Last accessed June 14, 2022. 2020.

16. Australian Bureau of Statistics. Population. Available via the Internet at https://www.abs.gov.au/statistics/people/population. Last accessed June 14, 2022. 2021.

17. Fisman DN, Greer AL, Brankston G, Hillmer M, O'Brien SF, Drews SJ, et al. COVID-19 Case Age Distribution: Correction for Differential Testing by Age. Ann Intern Med. 2021;174(10):1430-8.

18. Canadian Institutes for Health Information. COVID-19 hospitalization and emergency department statistics. Available via the Internet at https://www.cihi.ca/en/covid-19-hospitalization-and-emergency-department-statistics. Last accessed June 15, 2022. 2022.

19. Briggs AH, Goldstein DA, Kirwin E, Meacock R, Pandya A, Vanness DJ, et al. Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. Health Econ. 2021;30(3):699-707.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

20. Kirwin E, Rafferty E, Harback K, Round J, McCabe C. A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine. Pharmacoeconomics. 2021;39(9):1059-73.

21. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Glattino C, Ortiz-Ospina E, et al. COVID-19: Stringency Index. Our World In Data. Available via the Internet at https://ourworldindata.org/covid-stringency-index. Last accessed August 3, 2022. 2022.

22. Gohmann SF. A comparison of health care in Canada and the United States: the case of Pap smears. Med Care. 2010;48(11):1036-40.

23. Zajacova A, Siddiqi A. A comparison of health and socioeconomic gradients in health between the United States and Canada. Soc Sci Med. 2022;306:115099.

24. Fisher S, Bennett C, Hennessy D, Fines P, Jessri M, Bader Eddeen A, et al. Comparison of mortality hazard ratios associated with health behaviours in Canada and the United States: a population-based linked health survey study. BMC Public Health. 2022;22(1):478.

25. Galvani AP, Parpia AS, Pandey A, Sah P, Colón K, Friedman G, et al. Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic. Proc Natl Acad Sci U S A. 2022;119(25):e2200536119.

26. Razak F, Shin S, Naylor CD, Slutsky AS. Canada's response to the initial 2 years of the COVID-19 pandemic: a comparison with peer countries. CMAJ. 2022;194(25):E870-E7.

27. Fisman D. Universal healthcare and the pandemic mortality gap. Proc Natl Acad Sci U S A. 2022;119(29):e2208032119.

28. Aknin LB, Andretti B, Goldszmidt R, Helliwell JF, Petherick A, De Neve JE, et al. Policy stringency and mental health during the COVID-19 pandemic: a longitudinal analysis of data from 15 countries. Lancet Public Health. 2022;7(5):e417-e26.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

29. van Lith TJ, Sluis WM, Wijers NT, Meijer FJ, Kamphuis-van Ulzen K, de Bresser J, et al. Prevalence, risk factors, and long-term outcomes of cerebral ischemia in hospitalized COVID-19 patients - study rationale and protocol of the CORONIS study: A multicentre prospective cohort study. Eur Stroke J. 2022;7(2):180-7.

30. Hillis SD, Unwin HJT, Chen Y, Cluver L, Sherr L, Goldman PS, et al. Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study. Lancet. 2021;398(10298):391-402.

31. Sidik S**.** Heart disease after COVID: what the data say. Nature. 2022;608:26-8.

32. Ledford H**.** How common is long COVID? Why studies give different answers. Nature. 2022;606(7916):852-3.

33. Covid- Excess Mortality Collaborators**.** Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022;399(10334):1513-36.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Table: Mean and Standard Deviation for Oxford Pandemic Stringency Index in Canada and Comparator Countries, March 1, 2020 to May 1, 2022.

Country	Mean	SD	P-value
Canada	58.60	21.71	
Australia	54.88	18.76	<0.001
France	48.84	21.08	<0.001
United Kingdom	51.14	24.05	<0.001
United States	53.12	17.98	<0.001

NOTE: SD, standard deviation.

P-value for Wilcoxon rank-sum test for comparison with Canada.

medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary Figures: Oxford Pandemic Stringency Index by Date, Canada and Comparator Countries.

Stringency values plotted to May 1, 2022. Higher values indicate more stringent control measures.



medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2021.03.23.21253873; this version posted August 8, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .